Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 25%
Hold 42%
Sell 17%
Strong Sell 0%

Bulls say

RxSight Inc demonstrated a robust financial performance, highlighted by a gross margin of 71.6%, which represents a significant year-over-year increase of 980 basis points and exceeds market consensus. The company's revenue from Light Adjustable Lens (LAL) reached $28.5 million, marking a 60% increase, while revenue from the Light Delivery Device (LDD) was reported at $10.7 million, reflecting a 7% growth, both of which align closely with consensus estimates. Additionally, RxSight is expected to sustain double-digit growth fueled by increasing utilization rates and an expanding LDD installed base, positioning the company favorably for continued margin improvement.

Bears say

RxSight Inc. is experiencing a notable slowdown in its business performance, as evidenced by the deceleration in Light Adjustable Lens (LAL) utilization growth, which fell to +9% year-over-year in 4Q24, down from the previous growth range of +17%-22%. The company is facing challenging conditions in the U.S. cataract end market, with indications that U.S. intraocular lens sales may be flat or declining, which raises concerns about the sustainability of its market share amidst increased competition and a weakening macroeconomic environment. Furthermore, the downward revisions to earnings per share estimates for 2025 and 2026, as well as risks related to adoption hurdles and potential dilutive financing, contribute to a more negative outlook on RxSight's stock performance.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 25% recommend Buy, 42% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Hold consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.